Bryan, Garnier & Co's News

Galapagos: This opportunity will self-destruct in 60 days

BUY, Fair Value EUR61 vs. EUR57 (+10%)
News published on
August Tuesday 11, 2015

Galapagos released filgotinib’s 24w data from DARWIN-2 study in patients with an inadequate response to methotrexate who are DMARDs naïve. At 24w, filgotinib as a monotherapy showed good efficacy and a safety profile consistent with what was previously observed at 12w. These results trigger a 60-days opt-in period for ABBV.